Literature DB >> 18848589

Drug targeting and tumor heterogeneity.

You Han Bae1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18848589      PMCID： PMC2627764          DOI： 10.1016/j.jconrel.2008.09.074

Source DB:  PubMed          Journal:  J Control Release        ISSN： 0168-3659            Impact factor:   9.776


× No keyword cloud information.
  5 in total

Review 1.  Tumor heterogeneity and progression: conceptual foundations for modeling.

Authors:  L D Greller; F L Tobin; G Poste
Journal:  Invasion Metastasis       Date:  1996

Review 2.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

Authors:  H Maeda; J Wu; T Sawa; Y Matsumura; K Hori
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

3.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.

Authors:  S K Hobbs; W L Monsky; F Yuan; W G Roberts; L Griffith; V P Torchilin; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

4.  Folate receptor overexpression is associated with poor outcome in breast cancer.

Authors:  Lynn C Hartmann; Gary L Keeney; Wilma L Lingle; Teresa J H Christianson; Bindu Varghese; David Hillman; Ann L Oberg; Philip S Low
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

5.  Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles.

Authors:  Ho-Young Hwang; In-San Kim; Ick Chan Kwon; Yong-Hee Kim
Journal:  J Control Release       Date:  2008-02-20       Impact factor: 9.776
  5 in total
  30 in total

1.  Diseases originate and terminate by genes: unraveling nonviral gene delivery.

Authors:  Rajan Swami; Indu Singh; Wahid Khan; Sistla Ramakrishna
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

2.  Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles.

Authors:  Xiang-Hong Peng; Yiqing Wang; Donghai Huang; Yuxiang Wang; Hyung Juc Shin; Zhengjia Chen; Michael B Spewak; Hui Mao; Xu Wang; Ying Wang; Zhuo Georgia Chen; Shuming Nie; Dong M Shin
Journal:  ACS Nano       Date:  2011-11-04       Impact factor: 15.881

3.  Controlled release of doxorubicin from pH-responsive microgels.

Authors:  Mahrokh Dadsetan; K Efua Taylor; Chun Yong; Zeljko Bajzer; Lichun Lu; Michael J Yaszemski
Journal:  Acta Biomater       Date:  2012-09-25       Impact factor: 8.947

4.  Targeted drug delivery to tumors: myths, reality and possibility.

Authors:  You Han Bae; Kinam Park
Journal:  J Control Release       Date:  2011-06-06       Impact factor: 9.776

Review 5.  Challenges in design and characterization of ligand-targeted drug delivery systems.

Authors:  Silvia Muro
Journal:  J Control Release       Date:  2012-06-15       Impact factor: 9.776

6.  Polystyrene@poly(ar-vinylbenzyl)trimethylammonium-co-acrylic acid core/shell pH-responsive nanoparticles for active targeting and imaging of cancer cell based on aggregation induced emission.

Authors:  Yu Zhao; Bo Pang; Jie Chen; Lizhi Xiao; Hou Liu; Wenhui Lian; Tianxia Sun; Yingnan Jiang; Quan Lin
Journal:  Mikrochim Acta       Date:  2020-02-13       Impact factor: 5.833

Review 7.  Challenges in development of targeted liposomal therapeutics.

Authors:  Rupa R Sawant; Vladimir P Torchilin
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

8.  Enhanced siRNA delivery using a combination of an arginine-grafted bioreducible polymer, ultrasound, and microbubbles in cancer cells.

Authors:  Stelios Florinas; Hye Yeong Nam; Sung Wan Kim
Journal:  Mol Pharm       Date:  2013-04-05       Impact factor: 4.939

Review 9.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 10.  Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery.

Authors:  Emily Gullotti; Yoon Yeo
Journal:  Mol Pharm       Date:  2009 Jul-Aug       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.